Skip to evidence report

T.CD4_transitional: Studies

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

Subtype · 7,677 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 1–1,000 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for T.CD4_transitional
#Trait / studyIndividual trait IDMean IC score
1Allergic contact dermatitisFING0000006840.68
2Psoriatic arthritisGCST9024395637.32
3Psoriasis vulgaris (PheCode 696.41)GCST9047619035.00
4Papulosquamous disordersFING0000114434.49
5Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditionsUKBB0000051834.37
6Second line medication for Crohn's diseaseFING0000128434.15
7Autoimmune diseases excluding thyroid diseasesFING0000013234.12
8CD5/TNFRSF9 ratioGCST9031386233.75
9Psoriasis (PheCode 696.4)GCST9047618733.69
10Treatment/medication code - levothyroxine sodium | MedicationsUKBB0000084933.50
11Other/unspecified rheumatoid arthritisFING0000112633.50
12Psoriasis and related disorder (PheCode 696)GCST9047618633.21
13Reimbursement for rheumatic diseasesFING0000124733.02
14Asthma | Chronic lower respiratory diseasesUKBB0000005332.28
15Hypothyroidism NOS (PheCode 244.4)GCST9047565332.05
16Hypothyroidism (PheCode 244)GCST9047564731.96
17Asthma | respiratoryUKBB0000005431.84
18Thyroid problemsGCST9047527631.57
19Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditionsUKBB0000050931.12
20CXCL9 levelsGCST9046893531.10
21TNFRSF8 levelsGCST9047091530.88
22Hypothyroidism | endocrine/metabolicUKBB0000033530.56
23Atopic dermatitisFING0000012530.47
24Nasal polypFING0000085830.42
25Other hypothyroidism | Disorders of thyroid glandUKBB0000061130.01
26Hypothyroidism NOS | endocrine/metabolicUKBB0000033629.81
27HypothyroidismGCST9046813829.80
28Disorders of the thyroid glandFING0000046329.78
29Rheumatoid arthritisFING0000126729.44
30Asthma-related infectionsFING0000011829.26
31Dermatitis and eczemaFING0000040229.15
32FCRL6 levelsGCST9046920929.10
33Autoimmune diseasesFING0000013129.09
34Hypothyroidism, strict autoimmuneFING0000065628.82
35HypothyroidismGCST9020416728.77
36Asthma-related acute respiratory infectionsFING0000011728.33
37Type 1 diabetesGCST9000052928.22
38Asthma (childhood onset)GCST00780028.22
39PAFAH1B3 levelsGCST9047014528.22
40Atopic dermatitisGCST9002716128.18
41Lymphocyte countGCST9001874227.98
42CD5 levelsGCST9046864127.97
43Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044)GCST9004253527.74
44Prescriptions - levothyroxine | thyroid hormoneUKBB0000068727.48
45Prescriptions - thyroid hormone | hormoneUKBB0000070527.48
46Seropositive rheumatoid arthritis, strict definitionFING0000129727.35
47CD48/CRTAM ratioGCST9031383926.72
48Psoriasis vulgarisFING0000122426.56
49Noninfective enteritis and colitisFING0000088126.48
50Allergic disease (asthma, hay fever or eczema)GCST00503826.37
51Asthma (adult onset)GCST00779926.16
52AsthmaGCST01004226.08
53Suggestive for eosinophilic asthmaFING0000134425.94
54Chronic sinusitisFING0000029825.93
55Type 1 diabetesGCST9001379125.71
56Lymphocyte countGCST9002598425.66
57Multiple sclerosisGCST9047583325.58
58Eosinophill percentage (UKB data field 30210)GCST9046806925.46
59Takes medication for Thyroid problems?GCST9047527725.25
60CD160/KLRB1 ratioGCST9031373125.20
61Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditionsUKBB0000010125.15
62AsthmaGCST9046811225.09
63Asthma/COPD (KELA code 203)FING0000012124.89
64First line medication for Crohn's diseaseFING0000054424.82
65Chronic lower respiratory diseasesFING0000029024.76
66Lymphocyte countGCST9000231724.68
67lymphocyte (absolute count, mean, inv-norm transformed)GCST9047542624.64
68Lymphoid neoplasmsGCST9062474324.62
69Eosinophill count | Blood countUKBB0000020624.51
70Lymphoid neoplasms (somatic mutation group 2 phenocluster)GCST9062475024.48
71CXCL16 levelsGCST9046892824.38
72Other diseases of upper respiratory tractFING0000101224.31
73Asthma (only as main-diagnosis) (more control exclusions)FING0000011424.30
74TXNL1 levelsGCST9047099324.27
75SKAP1 levelsGCST9047064524.17
76EczemaGCST9046812624.17
77Eosinophill percentage | Blood countUKBB0000020724.13
78Other (seronegative) rheumatoid arthritis, wideFING0000091724.05
79HypothyroidismGCST9031932023.93
80MS-disease / Multiple SclerosisFING0000083923.82
81Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditionsUKBB0000010023.77
82CRTAM/VCAM1 ratioGCST9031428123.73
83Graves disease, strict definitionFING0000059223.71
84Crohn disease (strict definition, require KELA, min 2 HDR)FING0000036623.56
85PDCD1 levelsGCST9047018123.43
86Eosinophil percentage of white cellsGCST00460023.35
87HyperthyroidismGCST9046813623.16
88ThyrotoxicosisFING0000136023.11
89lymphocyte (absolute count, maximum, inv-norm transformed)GCST9047542323.06
90Asthma (more control exclusions)FING0000011322.83
91Type1 diabetes, definitions combined, early onsetFING0000138422.64
92Seropositive rheumatoid arthritis, wideFING0000129822.58
93Eosinophil countGCST00460622.51
94lymphocyte (absolute count, minimum, inv-norm transformed)GCST9047542922.51
95ITGAL levelsGCST9046963722.48
96NCR1 levelsGCST9047000922.41
97Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditionsUKBB0000009822.39
98CRTAM/FCRL6 ratioGCST9031427422.28
99Eosinophil percentage of white cellsGCST9000238222.24
100Type 1 diabetesGCST9001402322.19
101Eosinophill count (UKB data field 30150)GCST9046806822.18
102eosinophil (fraction, mean, inv-norm transformed)GCST9047530022.11
103Eosinophil percentage of granulocytesGCST00461722.09
104AsthmaGCST9001432522.07
105Lymphoid neoplasms (drug group 1 phenocluster)GCST9062474021.99
106Respiratory disease (confirmatory factor analysis Factor 11)GCST9030934521.86
107Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)FING0000075621.84
108Mosaic chromosomal alteration of the X chromosomeGCST9016528721.81
109PAG1 levelsGCST9047014721.79
110eosinophil (fraction, maximum, inv-norm transformed)GCST9047529721.73
111eosinophil (absolute count, mean, inv-norm transformed)GCST9047529121.57
112eosinophil (fraction, minimum, inv-norm transformed)GCST9047530321.30
113Nasal polyps (PheCode 471)GCST9047601921.28
114Sum eosinophil basophil countsGCST00462421.24
115GZMB levelsGCST9046942421.11
116CD244/CRTAM ratioGCST9031376321.09
117Non-cancer illness code, self-reported - asthma | Medical conditionsUKBB0000050621.08
118Neutrophil percentage of granulocytesGCST00462321.06
119Eosinophil countGCST9000229821.02
120Eosinophil countGCST9001873320.92
121GZMA/GZMB ratioGCST9031500720.91
122Rash and other nonspecific skin eruption (PheCode 687.1)GCST9047616720.89
123Allergic asthma (mode)FING0000006620.89
124eosinophil (absolute count, maximum, inv-norm transformed)GCST9047528820.88
125EndometriosisGCST9001861920.86
126Eosinophil countGCST9000229920.79
127Thyrotoxicosis with diffuse goitreFING0000136120.78
128Eosinophil countGCST9000238120.76
129Primary biliary cholangitisGCST9006144020.76
130CD6 levelsGCST9046864420.72
131Pulmonary fibrosisGCST9001868820.64
132PDCD1/TNFRSF8 ratioGCST9031561020.42
133Lymphoid neoplasms (B-cell phenocluster)GCST9062473620.19
134Lymphocyte count | Blood countUKBB0000041120.16
135PolyarthropathiesFING0000118020.13
136eosinophil (absolute count, minimum, inv-norm transformed)GCST9047529420.11
137Inflammatory bowel disease, strict (require KELA)FING0000067520.10
138HyperthyroidismGCST9031931920.08
139Lymphocyte count (UKB data field 30120)GCST9046808220.05
140PsoriasisGCST9001901620.00
141Rheumatoid arthritisGCST9001869019.95
142Coeliac diseaseGCST9046812019.89
143KLRB1 levelsGCST9046970919.78
144Type 1 diabetes, definitions combinedFING0000138019.77
145Childhood asthma (age<16) (more control exclusions)FING0000027019.76
146GZMH levelsGCST9046942519.73
147Left-hemisphere dorsal attention network to amygdala white-matter structural connectivityGCST9030270619.57
148Thyroid peroxidase antibody levels in pregnancyGCST9043520119.55
149Graves' diseaseGCST9001862719.51
150Lymphocyte countGCST9000238819.48
151PsoriasisFING0000122219.47
152Eosinophil countGCST9002598719.28
153Lymphocyte countGCST9000231619.25
154Seborrheic dermatitis (PheCode 690.1)GCST9047617119.18
155CD160/CXCL16 ratioGCST9031372819.16
156Rheumatoid arthritisGCST9013222419.16
157CD160 levelsGCST9046859919.10
158CRTAM/LY9 ratioGCST9031427818.99
159CD8A levelsGCST9046865518.96
160Erythematosquamous dermatosis (PheCode 690)GCST9047617018.94
161IL2RB levelsGCST9046958618.93
162Hypothyroidism, drug reimbursementFING0000065518.89
163Atopic/contact dermatitis due to other or unspecified (PheCode 939)GCST9047628918.87
164Ceramide (d18:2/22:0) levelsGCST9002468218.82
165Rheumatoid arthritisGCST9013222318.76
166Lymphocyte countGCST00462718.75
167IL15 levelsGCST9046955618.69
168HLAE/IL15 ratioGCST9031506118.67
169GZMA/GZMH ratioGCST9031500818.54
170Basal cell carcinoma (MTAG)GCST9013741118.50
171Thyroid peroxidase antibody positivity in pregnancyGCST9043520218.44
172Asthma and allergyFING0000011518.35
173MZB1 levelsGCST9046998718.33
174AsthmaGCST00686218.29
175Graves' disease (PheCode 242.1)GCST9047564418.26
176CD5/IL16 ratioGCST9031386118.23
177Allergy/adverse effect of penicillin | injuries & poisoningsUKBB0000002818.16
178GNLY levelsGCST9046937218.15
179Lichen simplex chronicus and prurigoFING0000072517.94
180HSIL lesion of the cervix uteriFING0000062417.89
181LTA levelsGCST9046981317.86
182Acute upper respiratory infectionsFING0000003417.79
183Vanillactate levelsGCST9019997817.75
184CLC levelsGCST9046876217.64
185Pain type(s) experienced in last month - Pain all over the body | PainUKBB0000063217.62
186Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditionsUKBB0000051317.60
187PALM2 levelsGCST9047015217.60
188KLRF1 levelsGCST9046971217.49
189OSMR levelsGCST9047013217.35
190Systemic lupus erythematosusGCST9001186617.30
191PsoriasisGCST9046814717.25
192Autoimmune hyperthyroidismFING0000013417.10
193Wheeze or whistling in the chest in last year | BreathingUKBB0000091217.10
194SIT1 levelsGCST9047064417.08
195Lichen ruber planus, wide definition including periferal and oral lichen planusFING0000072216.99
196Handedness (chirality/laterality) - Left-handed | Early life factorsUKBB0000030216.93
197Infective dermatitisFING0000067316.88
198GZMB/IL15 ratioGCST9031501516.74
199CCL17/PDGFB ratioGCST9031368816.69
200DNAJC21 levelsGCST9046901616.68
201Operation code - tonsillectomy +/- adenoids | OperationsUKBB0000056716.65
202Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health statusUKBB0000064116.59
203Nasal polyps | respiratoryUKBB0000049416.57
204Blood cell traits latent factor 20 (red cell)GCST9055926216.46
205SH2B3/TBL1X ratioGCST9031584116.35
206Age hay fever, rhinitis or eczema diagnosed | Medical conditionsUKBB0000001516.32
207IFNG levelsGCST9046951516.26
208Lichen sclerosus et atrophicusFING0000072316.21
209HSIL lesion of the cervix uteri, vagina or vulvaFING0000062516.19
210AsthmaGCST9047525916.18
211TNFRSF17 levelsGCST9047090816.14
212IL15/IL18BP ratioGCST9031514816.12
213IDO1 levelsGCST9046950616.10
214Monoclonal gammopathy of undetermined significanceGCST9062474515.94
215ChalazionFING0000026715.85
216Doctor diagnosed hayfever or allergic rhinitis | Medical informationUKBB0000019215.84
217DermatitisFING0000040115.75
218Neurofibromatosis, type 2FING0000086715.73
219SarcoidosisGCST9050348315.69
220CD7 levelsGCST9046864915.65
221Seronegative rheumatoid arthritisFING0000129615.61
222Thyroid peroxidase antibody positivity with euthyroid in pregnancyGCST9043520315.61
223Mouth/teeth dental problems - None of the above | MouthUKBB0000048915.59
224AsthmaGCST9047602415.51
225CD244/FCRL6 ratioGCST9031376515.48
226Crohn's disease NASFING0000036715.45
227Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555)GCST9047606515.45
228Coeliac diseaseFING0000031215.44
229CC2D1A/STAMBP ratioGCST9031366415.40
230CD79B/TNFRSF4 ratioGCST9031390315.34
231Left-hemisphere control network to amygdala white-matter structural connectivityGCST9030275715.28
232Obesity related asthmaFING0000089715.27
233ATOX1/SNAP29 ratioGCST9031337415.17
234RPE levelsGCST9047049515.14
235Myasthenia gravisGCST9043215615.06
236Mouth/teeth dental problems - Mouth ulcers | MouthUKBB0000048814.99
237HayfeverGCST9046813114.97
238Blood cell traits latent factor 9 (white cell)GCST9055925114.93
239Blood cell traits latent factor 23 (white cell)GCST9055926514.93
240RBFOX3 levelsGCST9047043214.88
241Cancer of urinary organs (incl. kidney and bladder) (PheCode 189)GCST9047559314.85
242Sicca syndrome [Sjögren]FING0000130414.78
243Nasal polyp | Other diseases of upper respiratory tractUKBB0000049314.71
244Vitamin B12 deficiency anaemiaFING0000144114.70
245MAVS/TBL1X ratioGCST9031539914.70
246CRTAM levelsGCST9046887114.69
247CD160/NCR1 ratioGCST9031373214.59
248Blood cell traits latent factor 17 (white cell)GCST9055925914.57
249IridocyclitisFING0000069614.52
250HippSubfield lh volume GC-ML-DG-headGCST9000267914.39
251Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)GCST9013222714.36
252Diseases of hair and hair follicles (PheCode 704)GCST9047620914.34
253GRAP2/SRC ratioGCST9031498914.23
254Inflammatory bowel diseaseGCST9043218214.22
255CD8 on Effector Memory CD8+ T cellGCST9000205614.19
256DTI TBSS L3 Cingulum hippocampus RGCST9038456014.17
257Regional enteritis (PheCode 555.1)GCST9047606614.13
258Wheeze or whistling in the chest in last year (UKB data field 2316)GCST9004361414.08
259Attendance/disability/mobility allowance - None of the above | Other sociodemographic factorsUKBB0000005913.89
260X-21285 levelsGCST9020057613.87
261Smoking status (weighted GWA)GCST9026730313.82
262DTI TBSS L1 Cingulum cingulate gyrus LGCST9038446313.81
263ICD10 O60: Preterm labor and deliveryGCST9045424213.79
264ICD10 N84: Polyp of female genital tractGCST9045421613.72
265Rheumatoid arthritisGCST00067913.66
266Type 1 diabetesGCST9043206613.65
267Preterm labour and deliveryFING0000120913.64
268GNLY/GZMA ratioGCST9031494913.62
269Early-onset myasthenia gravisGCST9009346513.60
270Basal cell carcinoma (PheCode 172.21)GCST9047558213.46
271Primary biliary cholangitisGCST00312913.46
272S100A11/S100A12 ratioGCST9031579813.44
273Asthma with exacerbation (PheCode 495.2)GCST9047602513.37
274IL5RA/TNFRSF13B ratioGCST9031516413.37
275Paraproteinemia (PheCode 270.32)GCST9047571013.28
276BMP7 levelsGCST9008815713.24
277N-acetyl-2-aminoadipate levelsGCST9020026813.23
278Primary biliary cholangitis (PBC)FING0000121113.22
279Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers)FING0000114313.21
280Dermatomycosis (PheCode 110.2)GCST9047556513.15
281Seborrhoeic dermatitisFING0000128213.13
282COPD/asthma/ILD related infectionsFING0000035313.11
283SarcoidosisFING0000127513.07
284Skin cancerGCST9047557513.05
285Medication use (drugs affecting bone structure and mineralization)GCST9001877312.96
286Lymphocyte percentage (UKB data field 30180)GCST9046808312.94
287CXCL10 levelsGCST9046892312.91
288CD27/NBL1 ratioGCST9031377412.89
289Lymphocyte percentage | Blood countUKBB0000041212.85
290IL1RL1 levelsGCST9046957412.72
291Right-hemisphere dorsal attention network to amygdala white-matter structural connectivityGCST9030281112.72
292PRG3 levelsGCST9047032312.66
293Ceramide (d18:2/24:1) levelsGCST9002468412.66
294Ulcerative colitisGCST00413312.65
295Atopic dermatitisGCST9001856412.64
296IFI30 levelsGCST9046950912.56
297CD27/TGFBR2 ratioGCST9031377612.55
298T1 FreeSurfer aseg MaskVol-to-eTIVGCST9038419212.53
299CD48/FCRL6 ratioGCST9031384012.50
300CRTAM/ICAM3 ratioGCST9031427612.47
301Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35)GCST9030936912.42
302Lymphocyte percentage of white cellsGCST9000238912.41
303CCL19 levelsGCST9046857112.39
304Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitorUKBB0000070612.37
305Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitorUKBB0000069412.37
306Interpolated Year when non-cancer illness first diagnosed | Medical conditionsUKBB0000037112.34
307Takes medication for Skin condition (ex. Eczema, Psoriasis)?GCST9047527512.32
308Other noninfective gastroenteritis and colitisFING0000107712.30
309Peripheral or central vertigo (PheCode 386.2)GCST9047590712.22
310lymphocyte (fraction, minimum, inv-norm transformed)GCST9047543812.17
311Asthma, unspecified (mode)FING0000012012.13
312Rosacea (PheCode 695.3)GCST9047617812.11
313Poisoning by antibiotics | injuries & poisoningsUKBB0000065312.09
314Crohn's disease of small intestineFING0000036912.02
315Chronic lymphocytic leukemiaGCST9062473811.89
316aparc-a2009s rh thickness G-temporal-middleGCST9000371411.87
317Erythematous conditions (PheCode 695)GCST9047617711.86
318Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41)GCST9066848511.86
319FCRL5/LY96 ratioGCST9031480311.86
320CRTAM/TNFRSF9 ratioGCST9031428011.83
321Disorders of orbitFING0000044911.83
322Blood cell traits latent factor 12 (red cell)GCST9055925411.82
323Pollen allergyFING0000117611.82
324MAPRE3 levelsGCST9046985911.82
325lymphocyte (fraction, mean, inv-norm transformed)GCST9047543511.81
326Omega-3 fatty acids to Omega-6 fatty acids ratioGCST9050239611.79
327IL22 levelsGCST9046958211.69
328Acute pancreatitisFING0000002711.69
329Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complicationsGCST9009311311.66
330KLRK1 levelsGCST9046971311.66
331Dissociative [conversion] disordersFING0000046811.65
332Other demyelinating diseases of the central nervous systemFING0000099511.64
333HippSubfield lh volume Hippocampal-tailGCST9000266811.58
334Systemic connective tissue disordersFING0000135011.57
335CD27/DLL1 ratioGCST9031377111.55
336FUT8/TNFSF14 ratioGCST9031489511.53
337Asthma-related pneumoniaFING0000011911.51
338aseg lh volume HippocampusGCST9000262411.49
339ICD10 N97.8: Female infertility of other originGCST9045422511.48
340CXCL16/NOTCH1 ratioGCST9031433911.44
341Late-onset myasthenia gravisGCST9009346611.43
342Ulcerative colitis (strict definition, require KELA, min 2 HDR)FING0000138811.42
343CRTAM/GZMA ratioGCST9031427511.40
344IGLC2 levelsGCST9046953611.37
345BCL2 levelsGCST9046843311.35
346KLF4 levelsGCST9046969411.35
347HippSubfield lh volume CA4-headGCST9000268211.32
348LTA4H levelsGCST9046981211.30
349Other non-epithelial cancer of skin (PheCode 172.2)GCST9047558011.24
350PRG2 levelsGCST9047032211.24
351Taking other prescription medications | MedicationUKBB0000081311.22
352CCL8 levelsGCST9042234611.16
353Lymphoid neoplasms (P-cell phenocluster)GCST9062473711.16
354CALCOCO1/IRAG2 ratioGCST9031360411.16
355CD101 levelsGCST9046859611.15
356PPP1R2/TBL1X ratioGCST9031572011.13
357Ulcerative rectosigmoiditisFING0000139411.10
358Mean corpuscular hemoglobin concentrationGCST9001874511.10
359PollinosisGCST9001868311.09
360Rheumatoid arthritis | musculoskeletalUKBB0000075711.08
361CA1/HMBS ratioGCST9031357311.07
362Treatment/medication code - ventolin 100micrograms inhaler | MedicationsUKBB0000086011.07
363Ulcerative colitisGCST9044679511.05
364SNRPB2 levelsGCST9047069711.04
365CXCL16 levelsGCST9024052411.03
366GZMA/TNFRSF8 ratioGCST9031501411.02
367APBB1IP/POLR2F ratioGCST9031330011.02
368IL18 levelsGCST9042841111.02
369PDCD5 levelsGCST9047018210.98
370FOXO3/SH2B3 ratioGCST9031488110.91
371Celiac disease (PheCode 557.1)GCST9004415810.86
372Omega-3 fatty acids to total fatty acids percentageGCST9050246010.77
373DCTN1/TRIAP1 ratioGCST9031443410.70
374DTI TBSS MD Superior corona radiata LGCST9038459710.69
375lymphocyte (fraction, maximum, inv-norm transformed)GCST9047543210.69
376TRAF2/WWP2 ratioGCST9031594310.66
377CRTAP levelsGCST9046887210.65
378MZB1/TNFRSF13B ratioGCST9031550910.64
379Cervicalgia (PheCode 761)GCST9047626710.64
380CD244 levelsGCST9046861110.61
381Avoided activities or situations because of previous stressful experience in past month | Traumatic eventsUKBB0000008310.60
382CRTAM/PDCD1 ratioGCST9031427910.57
383SRP14 levelsGCST9047074210.55
384ELOA/POLR2F ratioGCST9031464310.55
385Prescriptions - albuterol | beta2-agonist,bronchodilator,asthmaUKBB0000065810.54
386Prescriptions - beta2-agonist|bronchodilator|asthmaUKBB0000067010.54
387Disorders of sclera, cornea, iris and ciliary bodyFING0000045810.54
388ENO2/RWDD1 ratioGCST9031466710.43
389BLNK levelsGCST9046844810.42
390Allergic rhinitisFING0000007110.39
391KDM3A levelsGCST9046967110.36
392Other and unspecified tonsillitisFING0000095410.35
393PDCD1/TNFRSF4 ratioGCST9031560910.30
394Chromatiales abundance in stoolGCST9003231810.30
395Neoplasm of uncertain behavior of skin (PheCode 173)GCST9047558510.28
396IL2RA levelsGCST9046958510.27
397Melanomas of skin, dx or hx (PheCode 172.1)GCST9047557710.26
398Blood cell traits latent factor 3 (white cell)GCST9055924510.24
399Primary sclerosing cholangitisGCST00403010.22
400Overweight, obesity and other hyperalimentation | endocrine/metabolicUKBB0000062210.20
401FCRL6/GZMA ratioGCST9031480610.20
402Acute renal failureFING0000003010.16
403CCL17/CD69 ratioGCST9031368410.16
404Multiple myeloma or monoclonal gammopathy of undetermined significanceGCST9062474610.14
405Ulcerative colitisGCST9001871310.14
406ATP5IF1/METAP1D ratioGCST9031339110.07
407Urine N-acetylglutamate levels in chronic kidney diseaseGCST9026556910.01
408Plasma ascorbic acid 2-sulfate levels in chronic kidney diseaseGCST902648329.97
409Malignant neoplasm of thyroid gland, excluding all cancers (controls excluding all cancers)FING000007779.96
410Ulcerative colitis (PheCode 555.2)GCST900441559.96
411LHPP levelsGCST904697689.93
412Cervical cancerGCST900118169.92
413STX6 levelsGCST904707749.89
414Basal cell carcinomaGCST900134109.86
415Rhodanobacter abundance in stoolGCST900325369.83
416Rheumatoid arthritis (PheCode 714.1)GCST904762309.82
417Non-albumin protein levelsUKBB000005039.77
418CEACAM8/PGLYRP1 ratioGCST903140039.76
419ConjunctivitisFING000003469.76
420HippSubfield lh volume Whole-hippocampusGCST900026899.75
421CD6/EZR ratioGCST903138909.69
422Mean corpuscular hemoglobin concentrationGCST900023299.68
423Lymphoid leukemia, chronic (PheCode 204.12)GCST904756139.66
424ATP5IF1/LYN ratioGCST903133899.66
425Nasal polypsGCST904681439.59
426Plasma taurocholenate sulfate* levels in chronic kidney diseaseGCST902660409.59
427SH2D1A levelsGCST904706179.58
428TPSAB1 levelsGCST904709519.55
429LBR/LGALS8 ratioGCST903152949.51
430Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletalUKBB000007589.48
431Psoriatic arthropathiesFING000012259.48
432ACYP1 levelsGCST904682149.48
433DTI autoptx MD cgc l tractGCST903852249.46
434MPHOSPH8/USP8 ratioGCST903154799.42
435Ceramide (d18:2/22:0) levelsGCST900240549.42
436TIGIT levelsGCST904708659.41
437SMPD3 levelsGCST904706859.40
438CD74/NPDC1 ratioGCST903138959.39
439DTI autoptx L2 slf l tractGCST903851879.36
440DNAJB14 levelsGCST904272359.36
441Squamous cell carcinoma (PheCode 172.22)GCST904755839.35
442HSPA1A levelsGCST904694879.32
443IL15/NCR1 ratioGCST903151509.32
444DNMBP/WWP2 ratioGCST903145229.31
445Handedness (chirality/laterality) - Right-handed | Early life factorsUKBB000003039.30
446Myasthenia gravisGCST900930619.30
447Other specified disorders of external earFING000011049.25
448Lymphocyte percentage of white cellsGCST0046329.23
449APRT levelsGCST904683459.23
450Crohn's diseaseGCST904467939.23
451PAXX levelsGCST904701619.21
452Mean reticulocyte volumeGCST900259759.20
453CD27/NECTIN4 ratioGCST903137759.19
454Frequency of stair climbing in last 4 weeks | Physical activityUKBB000002669.16
455EDAR/LAT2 ratioGCST903145829.09
456Dizziness and giddiness (Light-headedness and vertigo) (PheCode 386.9)GCST904759089.09
457Crohn's diseaseGCST0041329.08
458LAT/LYN ratioGCST903152839.06
459HEXIM1/TBL1X ratioGCST903150539.05
460SH3GLB2 levelsGCST904706219.02
461Poultry consumptionGCST901329968.98
462GZMA/TNFRSF4 ratioGCST903150138.98
463Skin cancerGCST904751898.97
464CEP43/MPHOSPH8 ratioGCST903140198.97
465Ulcerative colitisGCST904753228.97
466Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers)FING000007728.96
467CXCL11/DKK1 ratioGCST903143348.94
468Cerebrospinal fluid methylmalonate (MMA) levelsGCST903182438.93
469Bipolar disorderGCST0037248.91
470GZMH/KLRD1 ratioGCST903150168.91
471MelanomaGCST900118098.90
472CRACR2A/LBR ratioGCST903142288.88
473EZR levelsGCST904691628.81
474Mean reticulocyte volume | Blood countUKBB000004518.79
475CD48/SLAMF7 ratioGCST903138428.77
476Basophil countGCST900022938.76
477Ratio of bis-allylic bonds to double bonds in lipidsGCST901327448.75
478PM: initial answer - Orange circle| Prospective memoryUKBB000006528.75
479PSAPL1 levelsGCST902423548.74
480mean corpuscular volume (MCV, minimum, inv-norm transformed)GCST904754748.71
481GRAP2/MAP4K5 ratioGCST903149828.71
482CD27 levelsGCST904686158.71
483Crohn's diseaseGCST904753188.68
484Omega-3 fatty acids to total fatty acids percentageGCST905024488.67
485LY6D/WFDC12 ratioGCST903153468.67
486C9 Carnitine levels in chronic kidney diseaseGCST902576828.66
487T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 78)GCST903206418.65
488ERBIN/LYN ratioGCST903146948.63
489CAPG levelsGCST904685378.63
490Infections of the skin and subcutaneous tissueFING000006708.62
491CDSN/WFDC12 ratioGCST903139998.60
492MAP2K6/TBL1X ratioGCST903153788.57
493DTI TBSS L3 Sagittal stratum LGCST903845558.57
494mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST904754448.55
495Diseases of the digestive systemFING000004298.55
496BACH1/CD2AP ratioGCST903134358.55
497Acute upper respiratory infections of multiple and unspecified sitesFING000000358.53
498Left-hemisphere salience/ventral attention network to amygdala white-matter structural connectivityGCST903027248.52
499DNA methylation-estimated granulocyte proportionsGCST900142878.51
500FUT8/RSPO1 ratioGCST903148918.50
501CD48 levelsGCST904686358.49
502PTPRC levelsGCST904703808.43
503NELL2/SEZ6L ratioGCST903155368.41
504PBLD levelsGCST904701638.41
505NBN levelsGCST904700028.37
506CataractsGCST900185948.36
507DNA methylation PhenoAge accelerationGCST900142928.36
508GRHPR levelsGCST904694008.35
509Right-hemisphere somatomotor network to amygdala white-matter structural connectivityGCST903027998.35
510Carboplatin drug response (IC50)GCST900117838.34
511IL10 levelsGCST904695468.33
512Average total household income before tax | HouseholdUKBB000000818.32
513Obesity | endocrine/metabolicUKBB000005448.32
514Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary AdministrationUKBB000008378.32
515CDSN/LY6D ratioGCST903139978.31
516DKK1/IPCEF1 ratioGCST903144718.31
517Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24)GCST903093588.28
518SUMF1 levelsGCST904707838.27
519Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classifiedFING000004328.27
520B2M levelsGCST904684098.27
521Obesity | Obesity and other hyperalimentationUKBB000005458.27
522Other arthritis (FG)FING000009648.25
523TP53BP1 levelsGCST904709368.22
524Never eat wheat vs no wheat restrictions (UKB data field 6144)GCST901329328.20
525Alcohol-induced chronic pancreatitisFING000000558.20
526GZMA/LTA ratioGCST903150128.18
527ROR1/THBD ratioGCST903157868.17
528IDP dMRI ProbtrackX L1 ifo rGCST900042598.15
529mean corpuscular volume (MCV, maximum, inv-norm transformed)GCST904754668.13
530mean corpuscular volume (MCV, mean, inv-norm transformed)GCST904754708.13
531PEAR1/PECAM1 ratioGCST903156418.10
532Octadecenedioylcarnitine (C18:1-DC) levelsGCST901999708.09
533IPCEF1/SERPINE1 ratioGCST903151848.08
534Thyrotoxicosis with or without goiter (PheCode 242)GCST904756438.03
535Chronic dermatitis due to solar radiation (PheCode 938.2)GCST904762888.03
536Principal component-derived dietary pattern 9GCST901330148.03
537Idiopathic pulmonary fibrosisFING000006598.03
538Thoracic or lumbosacral neuritis or radiculitis, unspecified (PheCode 763)GCST904762688.02
539Non-allergic asthma (mode) (more control exclusions)FING000008698.00
540INPP5J levelsGCST904696187.99
541PLXNB3/SNAP23 ratioGCST903156937.99
542Allergic conjunctivitisFING000000677.97
543IDP dMRI TBSS OD Posterior limb of internal capsule RGCST900044207.95
544NECTIN2/NPDC1 ratioGCST903155287.94
545BACH1/SNAP23 ratioGCST903134467.90
546T1 FreeSurfer BA lh BA2 exvivo volumeGCST903855347.90
547TNF/TNFRSF1B ratioGCST903159427.89
548UGDH levelsGCST904710067.87
549Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448)GCST901329687.86
550LBR/POLR2F ratioGCST903152977.86
551PPM1B levelsGCST904702967.86
552Diseases of white blood cells (PheCode 288)GCST904758127.86
553Benign leiomyoma with endometriosis (controls excluding all cancers)FING000001457.80
554MICB_MICA/TEK ratioGCST903154467.79
555T1 FreeSurfer aseg Right-choroid-plexusGCST903841707.79
556Lumbar disc prolapseFING000007357.78
557Long-standing illness, disability or infirmity | General healthUKBB000004097.77
558ARG1 levelsGCST904683507.76
559IPCEF1 levelsGCST904696247.74
560ENO2/PLXNA4 ratioGCST903146657.74
561GZMA levelsGCST904694237.72
562Mouth/teeth dental problems - Bleeding gums | MouthUKBB000004857.70
563Crohns diseaseGCST904681217.68
564Other acute lower respiratory infectionsFING000009217.67
565TSC1 levelsGCST904709727.67
566Biological Sibling: AsthmaGCST904763727.66
567Strenuous sports or other exercisesGCST0061007.66
568Mood swings | Mental healthUKBB000004827.65
569CWC15 levelsGCST904689207.65
570Treatment or medication use - insulin product (UKB data field 20003_1140883066)GCST900422267.64
571Chronic diseases of tonsils and adenoidsFING000002837.63
572CALCOCO1/TBC1D5 ratioGCST903136107.62
573IDP dMRI TBSS L1 Posterior limb of internal capsule RGCST900040937.62
574TNFRSF9 levelsGCST904709167.62
575SNAP23/TBL1X ratioGCST903158567.61
576MAP2K1 levelsGCST904698517.59
577PCBD1 levelsGCST904701667.58
578Prospective memory result | Prospective memoryUKBB000007137.56
579Melanomas of skin (PheCode 172.11)GCST904755787.55
580SMNDC1 levelsGCST904706817.54
581DAPP1/ITGB1BP2 ratioGCST903143887.54
582TALDO1 levelsGCST904708027.54
583IL32 levelsGCST904695917.54
584ZNF830 levelsGCST904711027.53
585Hair colour (natural, before greying): Red (UKB data field 1747_2)GCST900418377.53
586Number of attempts | Prospective memoryUKBB000005317.53
587F2R/SNX9 ratioGCST903147367.51
588mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST904754487.50
589Mean sphered cell volume (UKB data field 30270)GCST904680897.48
590GBP4 levelsGCST904693137.48
591Degenerative skin conditions and other dermatoses (PheCode 702)GCST904762027.48
592FCRL5/TNFRSF13B ratioGCST903148057.47
593CD27/TNFRSF9 ratioGCST903137787.45
594Prescriptions - antispasmodicUKBB000006667.43
595ALB/Globulin ratioUKBB000000207.42
596Vertiginous syndromes and other disorders of vestibular system (PheCode 386)GCST904759057.40
597Basophil countGCST900187267.40
598Rheumatoid arthritis and other inflammatory (PheCode 714)GCST904762287.39
599X-11550 levelsGCST902436487.38
600TNFRSF11A levelsGCST902776447.36
601Autoimmune hepatitisGCST900185657.35
602SELPLG levelsGCST904705687.35
603Chronic obstructive pulmonary disease in current smokersGCST900165937.33
604RILP levelsGCST904704717.33
605ICD10 N87: Dysplasia of cervix uteriGCST904542187.32
606Actinic keratosis (PheCode 702.1)GCST904762047.32
607Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditionsUKBB000003697.30
608RAP1A levelsGCST904704257.30
609FCRL5/ICAM3 ratioGCST903148027.29
610Nonspecific chest pain | circulatory systemUKBB000005277.29
611mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed)GCST904754427.26
612CDA levelsGCST904686607.26
613Never eat wheat vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144)GCST901329317.26
614SPINK2 levelsGCST904707227.26
615EBAG9/FKBP5 ratioGCST903145647.24
616CCR2 on CD14+ CD16- monocyteGCST900020047.24
617aparc-a2009s rh thickness G-oc-temp-med-LingualGCST900036987.23
618Treatment/medication code - ibuprofen | MedicationsUKBB000008477.20
619T1 FreeSurfer DK rh supramarginal volumeGCST903857877.17
620Ulcerative enterocolitisFING000013917.16
621mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST904754507.16
622CEP85 levelsGCST904687167.15
623MSRA/PRDX5 ratioGCST903154977.15
624ITGB7 levelsGCST904696477.14
625Chronic hepatitis B infectionGCST900185847.14
626HippSubfield lh volume CA4-bodyGCST900026837.13
627Mean sphered cell volume | Blood countUKBB000004527.11
628DAG1/F2R ratioGCST903143747.11
629Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80)GCST906685247.09
630Other contact dermatitisFING000009907.08
631Juvenile rheumatoid arthirtisFING000007067.06
632mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST904754467.06
633DTI TBSS MD Superior longitudinal fasciculus RGCST903846127.04
634Lung cancerGCST900186557.03
635Hepatic cancerGCST900186387.02
636Psoriasis (vulgaris), strict definitionFING000012237.02
637CDC27 levelsGCST904686646.98
638Ankylosing spondylitis, strict definitionFING000000906.98
639Other systemic involvement of connective tissue (FG)FING000011166.98
640Scar conditions and fibrosis of skin (PheCode 701.2)GCST904761986.98
641DTI TBSS L2 Superior longitudinal fasciculus LGCST903845176.97
642CASP10 levelsGCST904685426.97
643HippSubfield lh volume Whole-hippocampal-bodyGCST900026876.96
644ARHGAP25/RNF41 ratioGCST903133456.95
645HMBS/PKLR ratioGCST903150636.95
646PM: initial answer - Blue square | Prospective memoryUKBB000006516.94
647FOXO1/NFATC1 ratioGCST903148736.94
648Sporadic miscarriageGCST0118886.90
649Follicular lymphoma, hilmo (controls excluding all cancers)FING000005486.89
650CD27/CD79B ratioGCST903137706.88
651DTI autoptx L3 ifo l tractGCST903852056.88
652ITGB1BP2/TIA1 ratioGCST903152226.88
653Dementia due to Parkinson's disease (more control exclusions)FING000003926.86
654Dried fruit consumptionGCST901329806.86
655MICB or MICA levelsGCST904699056.84
656DTI TBSS L2 External capsule LGCST903845096.84
657IL5RA levelsGCST904696006.84
658Multiple myelomaGCST906247476.83
659BCR/FOXO1 ratioGCST903134906.83
660VSTM2B levelsGCST904710566.83
661Spondylopathies (FG)FING000013266.83
662CD27/TNFRSF13B ratioGCST903137776.80
663PROK1 levelsGCST904703366.78
664Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systemsUKBB000006256.78
665N-acetyl-1-methylhistidine levelsGCST902006906.76
666MED18/TBL1X ratioGCST903154156.76
667NFATC3 levelsGCST904700346.74
668Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers)FING000008466.73
669DTI autoptx FA slf l tractGCST903851336.73
670CD86 levelsGCST904686546.73
671CRACR2A/IRAG2 ratioGCST903142276.70
672CDH17/PTPRM ratioGCST903139436.69
673LRRC37A2 levelsGCST904698026.68
674Solitary pulmonary nodule (PheCode 514.2)GCST904760446.68
675PFKM levelsGCST906188026.67
676Bifidobacterium catenulatum abundance in stoolGCST900322246.67
677FCRL6/KLRD1 ratioGCST903148076.67
678LCN2/PGLYRP1 ratioGCST903153066.66
679Basal cell carcinoma, including avohilmo, excluding all cancers (controls excluding all cancers)FING000001436.66
680DTI autoptx MD str r tractGCST903852446.65
681Other intervertebral disc disordersFING000010636.64
682Left-hemisphere dorsal attention network to putamen white-matter structural connectivityGCST903027036.64
683N2-acetyl,N6,N6-dimethyllysine levelsGCST902006976.62
684Other circulatory problemGCST904752176.61
685GBP1 levelsGCST904693116.61
686Takes medication for asthma?GCST904752606.61
687AHSP/HMBS ratioGCST903132176.61
688Basal cell carcinoma, excluding all cancers (controls excluding all cancers)FING000001426.59
689PRKAR1A/SNAP23 ratioGCST903157286.59
690EBAG9/TGFB1 ratioGCST903145706.58
691Malignant neoplasm of lip, excluding all cancers (controls excluding all cancers)FING000007646.57
692Operative procedures - No procedure performed | Summary OperationsUKBB000005846.57
693Malignant neoplasm, excluding all cancers (controls excluding all cancers)FING000007806.57
694LCN2/S100A12 ratioGCST903153096.56
695FOXO1/USP8 ratioGCST903148796.56
696Cancer of bronchus; lung (PheCode 165.1)GCST904755736.56
697BTN3A2 levelsGCST904684816.55
698HAVCR2 levelsGCST904215156.53
699TNFRSF13B/TNFSF13B ratioGCST903159336.53
700AMOTL2 levelsGCST904682946.53
701Types of physical activity in last 4 weeks - None of the above | Physical activityUKBB000008726.52
702Ankylosing spondylitisFING000000896.50
703DTI TBSS MD Posterior limb of internal capsule LGCST903845916.49
704CDH17/PECAM1 ratioGCST903139426.48
705THBS2 levelsGCST904708546.47
706GFRA2 levelsGCST904693296.46
707MAVS/MED18 ratioGCST903153896.42
708HEXIM1/TRIAP1 ratioGCST903150546.41
709DTYMK levelsGCST904690496.41
710EDAR/ERBIN ratioGCST903145756.39
711Snoring | SleepUKBB000007846.38
712Hypoplasia of dental enamel, including avohilmoFING000006526.37
713HippSubfield lh volume GC-ML-DG-bodyGCST900026816.36
714SRC/TBL1X ratioGCST903158846.36
715Mean reticulocyte volumeGCST900023966.34
716EDAR/TACC3 ratioGCST903145896.32
717LPCAT2/SERPINB8 ratioGCST903153286.31
718Principal component-derived dietary pattern 26GCST901330316.30
719Ulcerative colitis, NASFING000013906.29
720SLAMF1 levelsGCST904706496.29
721AHCY/HSPA1A ratioGCST903132116.29
722CDH17/SPINT1 ratioGCST903139446.26
723Volume of right cortical nucleusGCST904750336.26
724CALCOCO1/CRACR2A ratioGCST903135986.25
725Disorders of plasma protein metabolism (PheCode 270.3)GCST904757096.24
726DTI autoptx MD slf r tractGCST903852426.23
727Cerebral aneurysm, nonrupturedFING000002636.22
728Belief that own life is meaningful | Happiness and subjective well-beingUKBB000000906.20
729DTI TBSS MD Superior longitudinal fasciculus LGCST903846136.20
730Lymphangioleiomyomatosis (sporadic)GCST0083116.19
731Mean corpuscular volume (UKB data field 30040)GCST904680866.18
732CPXM1/HBEGF ratioGCST903142196.18
733Mean reticulocyte volume (UKB data field 30260)GCST904680886.17
734Suppurative and unspecified otitis mediaFING000013466.16
735Tooth agenesis EXCLUDE clefts and syndromesFING000013686.16
736GOPC/IRAK4 ratioGCST903149546.16
737BOLA2 or BOLA2B levelsGCST904684606.15
738Symptoms involving digestive system (PheCode 561)GCST904760696.15
739Omega-3 fatty acids to total fatty acids percentageGCST905020876.14
740Destinations on discharge from hospital (recoded) - Usual Place of residence | Summary AdministrationUKBB000001676.09
741Principal component-derived dietary pattern 42GCST901330476.09
742Omega-3 fatty acid levelsGCST905024226.07
743SEMA4D levelsGCST904705736.06
7445alpha-pregnan-3beta,20alpha-diol monosulfate (2) levelsGCST901998546.04
745UNC5D levelsGCST904710105.99
746Red blood cell countGCST900187515.98
747Mean spheric corpuscular volumeGCST900023975.98
748N-acetylmethionine levelsGCST902002895.97
749Right-hemisphere visual network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027765.97
750Mean corpuscular volumeGCST900023925.97
751COL1A1 levelsGCST902407445.96
752Neutrophill percentage (UKB data field 30200)GCST904680935.95
753Medication use (immunosuppressants)GCST900187715.95
754TNFSF13B levelsGCST904709205.94
755Methods of discharge from hospital (recoded) - Discharged on clinical advice/consent | Summary AdministrationUKBB000004665.94
756COX5B/GFER ratioGCST903142005.92
757Hair colour (natural, before greying) - Dark brown | Sun exposureUKBB000002975.91
758Diseases of middle ear and mastoidFING000004275.91
759Lung adenocarcinomaGCST0047445.90
760KCTD5 levelsGCST904696705.89
761KIR3DL1 levelsGCST904696875.87
762Telomere length (principal component 1)GCST904351445.86
763CDKN2D/FOXO1 ratioGCST903139855.86
764ST13 levelsGCST904707515.85
765RIDA levelsGCST904704695.85
766Current employment status - Retired | EmploymentUKBB000001595.85
767Neutrophil percentage of white cellsGCST900023995.85
7683-methyl-2-oxobutyrate levelsGCST901996775.84
769MAP3K5/MAVS ratioGCST903153795.84
770Bread type - Wholemeal or wholegrain | DietUKBB000001075.84
771T1 FreeSurfer aseg Right-PallidumGCST903841645.82
772DTI autoptx L1 slf r tractGCST903851615.79
773Takes medication for Chronic lung diseases including COPD, Emphysema and Bronchitis?GCST904752735.79
774Ever SmokerFING000005225.79
775SLITRK2 levelsGCST904706705.78
776Polymyalgia rheumaticaFING000011885.77
777Attendance/disability/mobility allowance - Disability living allowance | Other sociodemographic factorsUKBB000000585.75
778GIMAP7 levelsGCST904693455.75
779SNX15 levelsGCST904706995.75
780Non-cancer illness year/age first occurred | Medical conditionsUKBB000005235.75
781TOR1AIP1 levelsGCST904709355.74
782CCL5/TACC3 ratioGCST903137075.72
783Fruit intake (weighted GWA)GCST902672835.72
784C5 levelsGCST904685005.71
785TRAF3 levelsGCST904709575.71
786General happiness | Happiness and subjective well-beingUKBB000002805.70
787Current SmokerFING000003715.69
788ADAM12 levelsGCST904682165.69
789APBB1IP levelsGCST904683275.67
790CXCL5/PLXNA4 ratioGCST903143515.66
791Hair colour (natural, before greying): Dark brown (UKB data field 1747_4)GCST900418395.65
792Neutrophill percentage | Blood countUKBB000004985.65
793IL2RA/NCR1 ratioGCST903151615.65
794Principal component-derived dietary pattern 21GCST901330265.63
795JCHAIN levelsGCST904696615.60
796Mean corpuscular volume | Blood countUKBB000004495.59
797DTI TBSS MD Cingulum cingulate gyrus LGCST903846075.59
798FCRL5 levelsGCST904692085.59
799LY96 levelsGCST904698235.58
800FOXO1/MAP4K5 ratioGCST903148725.58
801Dried fruit likingGCST900947565.57
802CD69/EDAR ratioGCST903138755.57
803DTI TBSS L2 Posterior thalamic radiation RGCST903845045.57
804Symptoms concerning nutrition, metabolism, and development (PheCode 1002)GCST904755565.57
805STIP1 levelsGCST904707645.57
806CXCL5/MESD ratioGCST903143505.56
807How are people in household related to participant - Husband, wife or partner | HouseholdUKBB000003305.55
808Crohn's disease of large intestineFING000003685.55
809Other and unspecified psoriasisFING000009505.54
810Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80)GCST906687585.54
811CALCOCO1/TJAP1 ratioGCST903136115.54
812APP/HBEGF ratioGCST903133245.53
813Cooked vegetable intake | DietUKBB000001475.52
814VEGFB levelsGCST904710355.51
815Plasma N-acetyltaurine levels in chronic kidney diseaseGCST902656005.51
816CD84/F2R ratioGCST903139125.50
817WASL levelsGCST904710705.49
818BA-exvivo lh volume BA2GCST900028365.49
819IDP dMRI TBSS ISOVF Genu of corpus callosumGCST900044795.48
820Tobacco use disorder | mental disordersUKBB000008245.48
821Pregnenolone sulfate levelsGCST901998735.48
822rfMRI connectivity (ICA100 edge 605)GCST900054585.47
823GMPR2 levelsGCST904693675.46
824UrticariaFING000014085.46
825DTI TBSS L3 Genu of corpus callosumGCST903845265.45
826AXIN1/MAVS ratioGCST903134145.45
827TNFSF12/TNFSF13 ratioGCST903159415.44
828Colitis, primary sclerosing, strict definitionFING000003135.43
829DTI autoptx L1 cst l tractGCST903851475.42
830TNFRSF4 levelsGCST904709135.42
831Cancer within the respiratory system (PheCode 165)GCST904755715.42
832Margaroylcarnitine (C17) levelsGCST901999295.40
833T1 CAT volume L VIIIaGCST903841275.40
834Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers)FING000010675.40
835CEP43/USP8 ratioGCST903140225.39
836NELL1 levelsGCST902424815.39
837KAZN levelsGCST904696665.38
838DLG4 levelsGCST904690015.37
839GSTA4 levelsGCST902412835.36
840T1 CAT volume R RightThalamusGCST903840975.36
841GP6/HPCAL1 ratioGCST903149635.36
842KYNU/SCLY ratioGCST903152655.34
843F11R/SORT1 ratioGCST903147265.34
844MAN2B2 levelsGCST904698445.33
845Sources of admission to hospital (recoded) - Usual Place of residence | Summary AdministrationUKBB000007865.33
846Type 1 diabetesGCST900187055.32
847Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74)GCST906685185.31
848BCR/ITGB1BP2 ratioGCST903134945.31
849DTI TBSS L3 Superior corona radiata LGCST903845495.31
850TP53I3 levelsGCST904709375.31
851Left-hemisphere somatomotor network to left-hemisphere control network white-matter structural connectivityGCST903026735.31
852Citrulline levelsGCST902004035.30
853FASLG levelsGCST904691915.29
854DTI TBSS MD Superior corona radiata RGCST903845965.28
855DBNL/EDAR ratioGCST903144165.28
856IDP dMRI ProbtrackX L1 str lGCST900042695.27
857ESAM/FUT8 ratioGCST903147115.27
858Peripheral enthesopathies and allied syndromes | musculoskeletalUKBB000006405.27
859CLEC4D/CLEC6A ratioGCST903141095.26
860Dermatitis due to ingested foodFING000004035.24
861T1 FreeSurfer a2009s lh S postcentral areaGCST903847345.23
862IDP dMRI TBSS L1 Retrolenticular part of internal capsule RGCST900040955.22
863Bread type: Wholemeal or wholegrain (UKB data field 1448_3)GCST901329665.22
864Mean corpuscular hemoglobin concentrationGCST900023285.21
865Mean corpuscular hemoglobin concentrationGCST900023915.21
866BOC levelsGCST904684585.21
867CD300A levelsGCST904686195.20
868Left-hemisphere default mode network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027625.20
869RAPGEF2 levelsGCST904704265.20
870Internal derangement of knee (PheCode 835)GCST904762825.19
871IL15/KLRD1 ratioGCST903151495.18
872Mean corpuscular hemoglobinGCST900023905.16
873Malignant neoplasm of kidney, except pelvis (PheCode 189.11)GCST904755975.15
874Uterine fibroidsGCST904619585.14
875Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905020745.14
876All pneumoniaeFING000000655.13
877C1R levelsGCST904684935.12
878DCTN6/TDRKH ratioGCST903144365.11
879Methods of admission to hospital (recoded) - Elective admission: Booked | Summary AdministrationUKBB000004615.11
880SUOX levelsGCST904707855.10
881CA3/HMBS ratioGCST903135845.09
882TRIM21 levelsGCST904709645.09
883AsthmaGCST900860475.07
884Mean corpuscular volumeGCST0046025.07
885CHMP1A/RHOC ratioGCST903140535.07
886FOXO3 levelsGCST904692665.07
887F2R/TNFRSF14 ratioGCST903147395.07
888T1 CAT volume R RightPutamenGCST903841015.04
889SPTLC1 levelsGCST904271305.04
890TNFSF12 levelsGCST902748465.03
891Skin cancer | neoplasmsUKBB000007725.02
892Educational attainmentGCST0025985.02
893ENO2/HCLS1 ratioGCST903146605.01
894HNRNPUL1 levelsGCST904694705.01
895T1 FreeSurfer DKT rh supramarginal volumeGCST903843775.00
896TFRC levelsGCST904708405.00
897Number of days/week walked 10+ minutes | Physical activityUKBB000005355.00
898EFNA4/TNFRSF9 ratioGCST903146064.99
899MINPP1 levelsGCST902419784.99
900Trouble falling asleep when you first go to bedGCST904763854.98
901EDAR/SNAP23 ratioGCST903145874.98
902DTI autoptx FA ifo r tractGCST903851254.98
903DOK2/PDLIM7 ratioGCST903145354.98
904Acquired hypothyroidism (PheCode 244.2)GCST904756504.97
905Sjögren's syndromeGCST900187004.97
906TNFRSF14/TNFSF14 ratioGCST903159364.97
907TNFRSF19 levelsGCST900889474.97
908PRKAB1 levelsGCST904703244.96
909TBCA levelsGCST904708124.95
910Mean corpuscular haemoglobin (UKB data field 30050)GCST904680844.95
911SIGLEC1/SSC5D ratioGCST903158444.95
912PPP1R14D levelsGCST904703034.94
913ZNRD2 levelsGCST904711034.94
914SnoringGCST0097624.93
915NT5C levelsGCST904700924.93
916FUT8/PDGFA ratioGCST903148904.93
917neutrophil (fraction, mean, inv-norm transformed)GCST904755384.92
918Beta-hydroxyisovaleroylcarnitine levelsGCST901998024.92
919Eosinophil count varianceGCST905656894.91
920AHNAK levelsGCST904682614.90
921AXIN1/ITGB1BP2 ratioGCST903134124.90
922Osteopenia or other disorder of bone and cartilage (PheCode 743.9)GCST904762614.90
923Other dorsopathies, not elsewhere classifiedFING000010414.90
924BleedingFING000002194.89
925SIRT1 levelsGCST904706414.88
926Mean corpuscular haemoglobin | Blood countUKBB000004474.88
927Active to sedentary transition probabilityGCST900614294.87
928F5 levelsGCST904464664.87
929DAB2/FKBP1B ratioGCST903143624.87
930Left-hemisphere dorsal attention network to right-hemisphere salience/ventral attention network white-matter structural connectivityGCST903026974.87
931CD40LG/TRAF2 ratioGCST903138284.86
932DAG1/DBNL ratioGCST903143724.86
933Human herpes virus 7 U14 antibody levelsGCST900069094.86
934PSIP1 levelsGCST904703544.85
935CSNK1D levelsGCST904688884.83
936IL16 levelsGCST904695574.83
937Other cancerGCST904751814.83
938Hernia abdominopelvic cavityGCST900860874.82
939Non-cancer illness code, self-reported - hiatus hernia | Medical conditionsUKBB000005154.81
940Actinic keratosisFING000000134.81
941PLAUR levelsGCST900120514.81
942DTI autoptx MD fma tractGCST903852304.80
943NCAN levelsGCST906185594.77
944Dried fruit intake | DietUKBB000001934.76
945APEX1 levelsGCST904683294.75
946DTI autoptx L3 slf r tractGCST903852154.75
947HTRA2/SIAE ratioGCST903150974.75
948DTI TBSS MD Posterior thalamic radiation RGCST903846004.74
949FOXO1/IRAK4 ratioGCST903148704.74
950F-caffeinated/sweet liking (derived food-liking factor)GCST900947204.73
951S100A12 levelsGCST904705134.73
952Fluid intelligence score decline (difference score)GCST905658624.73
953TXNDC15 levelsGCST904709904.72
954Atrophic disorders of skinFING000001294.72
955Mental and behavioural disorders due to use of tobacco | Mental and behavioural disorders due to psychoactive substance useUKBB000004604.71
956Avocado likingGCST900946944.70
957Mean corpuscular hemoglobinGCST0046304.69
958MED18/TACC3 ratioGCST903154144.68
959LSP1 levelsGCST904698114.67
960CRYBB1 levelsGCST904688744.67
961Ectopic pregnancyFING000004874.67
962Back pain (PheCode 760)GCST904762664.67
963Nervonoylcarnitine (C24:1) levelsGCST902001434.66
964PXN levelsGCST904703964.63
965IGSF8/NECTIN2 ratioGCST903151404.63
966FCER1A levelsGCST904691984.63
967INSR levelsGCST904696234.62
968CA1 levelsGCST904685104.62
969IDP T1 FIRST left hippocampus volumeGCST900024444.61
970PSME2 levelsGCST904703614.61
971DNAJA2/PLXNA4 ratioGCST903145044.60
972ITGB1BP2/USP8 ratioGCST903152234.60
973PIKFYVE levelsGCST904702354.60
974EDAR/F2R ratioGCST903145774.60
975Cleft hard palate NOSFING000003064.60
976aparc-DKTatlas rh thickness lingualGCST900035824.60
977Athlete's foot (PheCode 110.12)GCST904755634.59
978F2R levelsGCST904691684.59
979LBR levelsGCST904697444.59
980IPCEF1/SPARC ratioGCST903151864.58
981LAYN/PTPRN2 ratioGCST903152904.58
982Red blood cell countGCST900023644.57
983DTI TBSS L3 Posterior thalamic radiation RGCST903845524.57
984CLIC5 levelsGCST904217404.56
985GALNT10/SEMA7A ratioGCST903149154.56
986ENO3 levelsGCST904691114.56
987Excessive vomiting in pregnancyFING000005234.55
988DTI TBSS L1 Anterior corona radiata RGCST903844504.55
989neutrophil (fraction, maximum, inv-norm transformed)GCST904755354.54
990PARP1 levelsGCST904701604.54
991SNAP23/TXLNA ratioGCST903158574.54
992Smoking status (standard GWA)GCST902673024.54
993AHSP/BLVRB ratioGCST903132144.54
994Intrinsic epigenetic age accelerationGCST900142904.53
995Left-hemisphere limbic network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027314.53
996Loneliness, isolation | Mental healthUKBB000004084.53
997Wegener granulomatosisFING000014464.52
998PEBP1 levelsGCST904702054.52
999DTI autoptx FA ifo l tractGCST903851244.51
1000Lung cancerGCST0047484.51